MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 13, 2005; DOI: 10.1124/mol.104.002725


0026-895X/05/6704-1315-1324$20.00
Mol Pharmacol 67:1315-1324, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.002725v1
67/4/1315    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duca, L.
Right arrow Articles by Debelle, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duca, L.
Right arrow Articles by Debelle, L.
Original Article

Elastin Peptides Activate Extracellular Signal-Regulated Kinase 1/2 via a Ras-Independent Mechanism Requiring Both p110{gamma}/Raf-1 and Protein Kinase A/B-Raf Signaling in Human Skin Fibroblasts

Laurent Duca, Elise Lambert, Romain Debret, Bernard Rothhut, Charlotte Blanchevoye, Frédéric Delacoux, William Hornebeck, Laurent Martiny, and Laurent Debelle

Laboratory of Biochemistry, Unité Mixte Recherche Centre National de la Recherche Scientifique 6198, IFR53 Biomolécules, Faculty of Sciences, University of Reims Champagne-Ardenne, Moulin de la Housse, Reims, France (L.Du., E.L., R.D., B.R., C.B., F.D., W.H., L.M., L.De.); and EA 2070, IFR53 Biomolécules, Faculty of Pharmacy, University of Reims Champagne-Ardenne, Reims, France (R.D.)

Abstract

Elastin peptides (EPs) produced during cancer progression bind to the elastin binding protein (EBP) found at the surface of dermal fibroblasts, leading to the expression of collagenase-1 gene. The production of this enzyme involved in stromal reaction is caused by the sustained activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway via cAMP/protein kinase A (PKA) and phosphatidylinositol 3-kinase (PI3K). However, the mechanism of these signaling events remains unknown. We show that {kappa}-elastin ({kappa}E), a commonly used EP, induces maximum phosphorylation of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)1/2 and ERK1/2 after 30 min. The simultaneous inhibition of PKA and PI3K, by N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide (H89) and 2-(4-morpholynil)-8-phenyl-4H-1-bemzopyran-4-one (LY294002), respectively, blocked MEK1/2 and ERK1/2 phosphorylation, as did lactose, an EBP antagonist. {kappa}E induced Raf-1 phosphorylation and activation in a PI3K-dependent manner. In our system, the PI3K p110{gamma} is expressed and activated by {beta}{gamma}-derived subunits from a pertussis toxin-sensitive G protein after fibroblast stimulation. Pertussis toxin also blocks the Raf-1/MEK1/2/ERK1/2 phosphorylation cascade. In addition, we found that B-Raf is expressed in dermal fibroblasts and activated in a PKA-dependent manner after {kappa}E treatment, thereby integrating PKA signals to MEK1/2. It is noteworthy that Ras involvement was excluded because ERK1/2 activation by {kappa}E was not blocked in RasN17-transfected fibroblasts. Together, our results identify a novel Ras-independent ERK1/2 activation system in which p110{gamma}/Raf-1/MEK1/2 and PKA/B-Raf/MEK1/2 cooperate to activate ERK1/2. Thus, p110{gamma} and B-Raf seem to be important modulators of dermal fibroblasts physiology and should now qualify as therapeutic targets in strategies aiming at limiting elastin degradation contribution to cancer progression.


Received May 13, 2004; accepted January 12, 2005

Address correspondence to: Dr. Laurent Debelle, Université de Reims Champagne Ardenne, UFR Sciences Exactes et Naturelles, Laboratoire de Biochimie, UMR CNRS 6198, IFR53 Biomolécules, Moulin de la Housse, BP 1039, 51687 REIMS Cedex 2, France. E-mail: laurent.debelle{at}univ-reims.fr




This article has been cited by other articles:


Home page
J. Immunol.Home page
T. Baranek, R. Debret, F. Antonicelli, B. Lamkhioued, A. Belaaouaj, W. Hornebeck, P. Bernard, M. Guenounou, and R. Le Naour
Elastin Receptor (Spliced Galactosidase) Occupancy by Elastin Peptides Counteracts Proinflammatory Cytokine Expression in Lipopolysaccharide-Stimulated Human Monocytes through NF-{kappa}B Down-Regulation
J. Immunol., November 1, 2007; 179(9): 6184 - 6192.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Robinet, H. Millart, F. Oszust, W. Hornebeck, and G. Bellon
Binding of elastin peptides to S-Gal protects the heart against ischemia/reperfusion injury by triggering the RISK pathway
FASEB J, July 1, 2007; 21(9): 1968 - 1978.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Duca, C. Blanchevoye, B. Cantarelli, C. Ghoneim, S. Dedieu, F. Delacoux, W. Hornebeck, A. Hinek, L. Martiny, and L. Debelle
The Elastin Receptor Complex Transduces Signals through the Catalytic Activity of Its Neu-1 Subunit
J. Biol. Chem., April 27, 2007; 282(17): 12484 - 12491.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. J. Broekelmann, B. A. Kozel, H. Ishibashi, C. C. Werneck, F. W. Keeley, L. Zhang, and R. P. Mecham
Tropoelastin Interacts with Cell-surface Glycosaminoglycans via Its COOH-terminal Domain
J. Biol. Chem., December 9, 2005; 280(49): 40939 - 40947.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics